Unwanted disorders and xenogeneic graft‐versus‐host disease in experimental immunodeficient mice: How to evaluate and how to report
Abstract Human‐derived tumor models are essential for preclinical development of new anticancer drug entities. Generating animal models bearing tumors of human origin, such as patient‐derived or cell line–derived xenograft tumors, is dependent on immunodeficient strains. Tumor‐bearing immunodeficien...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Animal Models and Experimental Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ame2.12509 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087789043187712 |
|---|---|
| author | Seyed Mostafa Monzavi Samad Muhammadnejad Vahid Mansouri Hami Ashraf Naser Ahmadbeigi |
| author_facet | Seyed Mostafa Monzavi Samad Muhammadnejad Vahid Mansouri Hami Ashraf Naser Ahmadbeigi |
| author_sort | Seyed Mostafa Monzavi |
| collection | DOAJ |
| description | Abstract Human‐derived tumor models are essential for preclinical development of new anticancer drug entities. Generating animal models bearing tumors of human origin, such as patient‐derived or cell line–derived xenograft tumors, is dependent on immunodeficient strains. Tumor‐bearing immunodeficient mice are susceptible to developing unwanted disorders primarily irrelevant to the tumor nature; and if get involved with such disorders, reliability of the study results will be undermined, inevitably confounding the research in general. Therefore, a rigorous health surveillance and clinical monitoring system, along with the establishment of a strictly controlled barrier facility to maintain a pathogen‐free state, are mandatory. Even if all pathogen control and biosafety measures are followed, there are various noninfectious disorders capable of causing tissue and multiorgan damage in immunodeficient animals. Therefore, the researchers should be aware of sentinel signs to carefully monitor and impartially report them. This review discusses clinical signs of common unwanted disorders in experimental immunodeficient mice, and how to examine and report them. |
| format | Article |
| id | doaj-art-9bb45b87405c4d55b557d77c66e70f5a |
| institution | Kabale University |
| issn | 2576-2095 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Animal Models and Experimental Medicine |
| spelling | doaj-art-9bb45b87405c4d55b557d77c66e70f5a2025-02-06T03:52:55ZengWileyAnimal Models and Experimental Medicine2576-20952025-01-0181202910.1002/ame2.12509Unwanted disorders and xenogeneic graft‐versus‐host disease in experimental immunodeficient mice: How to evaluate and how to reportSeyed Mostafa Monzavi0Samad Muhammadnejad1Vahid Mansouri2Hami Ashraf3Naser Ahmadbeigi4Gene Therapy Research Center, Digestive Diseases Research Institute Tehran University of Medical Sciences Tehran IranGene Therapy Research Center, Digestive Diseases Research Institute Tehran University of Medical Sciences Tehran IranGene Therapy Research Center, Digestive Diseases Research Institute Tehran University of Medical Sciences Tehran IranGene Therapy Research Center, Digestive Diseases Research Institute Tehran University of Medical Sciences Tehran IranGene Therapy Research Center, Digestive Diseases Research Institute Tehran University of Medical Sciences Tehran IranAbstract Human‐derived tumor models are essential for preclinical development of new anticancer drug entities. Generating animal models bearing tumors of human origin, such as patient‐derived or cell line–derived xenograft tumors, is dependent on immunodeficient strains. Tumor‐bearing immunodeficient mice are susceptible to developing unwanted disorders primarily irrelevant to the tumor nature; and if get involved with such disorders, reliability of the study results will be undermined, inevitably confounding the research in general. Therefore, a rigorous health surveillance and clinical monitoring system, along with the establishment of a strictly controlled barrier facility to maintain a pathogen‐free state, are mandatory. Even if all pathogen control and biosafety measures are followed, there are various noninfectious disorders capable of causing tissue and multiorgan damage in immunodeficient animals. Therefore, the researchers should be aware of sentinel signs to carefully monitor and impartially report them. This review discusses clinical signs of common unwanted disorders in experimental immunodeficient mice, and how to examine and report them.https://doi.org/10.1002/ame2.12509animal modelsgraft‐versus‐host diseasehealth surveillancepreclinical drug evaluationxenograft model antitumor assays |
| spellingShingle | Seyed Mostafa Monzavi Samad Muhammadnejad Vahid Mansouri Hami Ashraf Naser Ahmadbeigi Unwanted disorders and xenogeneic graft‐versus‐host disease in experimental immunodeficient mice: How to evaluate and how to report Animal Models and Experimental Medicine animal models graft‐versus‐host disease health surveillance preclinical drug evaluation xenograft model antitumor assays |
| title | Unwanted disorders and xenogeneic graft‐versus‐host disease in experimental immunodeficient mice: How to evaluate and how to report |
| title_full | Unwanted disorders and xenogeneic graft‐versus‐host disease in experimental immunodeficient mice: How to evaluate and how to report |
| title_fullStr | Unwanted disorders and xenogeneic graft‐versus‐host disease in experimental immunodeficient mice: How to evaluate and how to report |
| title_full_unstemmed | Unwanted disorders and xenogeneic graft‐versus‐host disease in experimental immunodeficient mice: How to evaluate and how to report |
| title_short | Unwanted disorders and xenogeneic graft‐versus‐host disease in experimental immunodeficient mice: How to evaluate and how to report |
| title_sort | unwanted disorders and xenogeneic graft versus host disease in experimental immunodeficient mice how to evaluate and how to report |
| topic | animal models graft‐versus‐host disease health surveillance preclinical drug evaluation xenograft model antitumor assays |
| url | https://doi.org/10.1002/ame2.12509 |
| work_keys_str_mv | AT seyedmostafamonzavi unwanteddisordersandxenogeneicgraftversushostdiseaseinexperimentalimmunodeficientmicehowtoevaluateandhowtoreport AT samadmuhammadnejad unwanteddisordersandxenogeneicgraftversushostdiseaseinexperimentalimmunodeficientmicehowtoevaluateandhowtoreport AT vahidmansouri unwanteddisordersandxenogeneicgraftversushostdiseaseinexperimentalimmunodeficientmicehowtoevaluateandhowtoreport AT hamiashraf unwanteddisordersandxenogeneicgraftversushostdiseaseinexperimentalimmunodeficientmicehowtoevaluateandhowtoreport AT naserahmadbeigi unwanteddisordersandxenogeneicgraftversushostdiseaseinexperimentalimmunodeficientmicehowtoevaluateandhowtoreport |